Vonoprazan – A quick snapshot of its patent landscape
| Region | Key Patent(s) | Filed / Granted | Main Coverage | Current Status |
|--------|---------------|-----------------|----------------|----------------|
| Japan | JP 2008-063000 (composition & method of use) | 2008 / 2010 | The core chemical structure and its use in acid‑related disorders | Expiry 2030 (for the first‑generation composition patent; Otsuka has additional, later‑issued patents covering specific formulations that run to 2035–2036) |
| United States | US 2014/0214161 (potassium‑competitive acid blocker) | 2014 / 2015 | The same core compound and its use for GERD, ulcers, etc. | Expiry 2032 (first‑generation composition patent) |
| European Union | EP 2 245 041 (composition & use) | 2009 / 2013 | Core structure & acid‑suppression indications | Expiry 2030 |
| Other major markets | Multiple secondary patents covering delivery systems, combinations, and specific dosage forms (e.g., “sustained‑release” tablets, “film‑coat” formulations) | Various | Many still in force through the 2030s, depending on the specific claim | Varied – many still active; some have lapsed in certain countries |
What does this mean for you?
1. First‑generation composition patents (the ones that cover the core chemical entity and its primary therapeutic uses) are still in force worldwide and will remain so until roughly 2030–2032. This means that any generic version of vonoprazan that uses the same core molecule and the same indication is still protected by these patents.
2. Secondary patents – Otsuka (and its licensees) have applied for, and in many jurisdictions have been granted, patents on specific delivery methods (e.g., enteric‑coated tablets), fixed‑dose combinations (with other gastro‑protective agents), and even specific manufacturing processes. These can extend the effective exclusivity of the brand even after the core composition patent expires, and they typically run a few years beyond the primary patent.
3. Patent expiry in the U.S. and EU – In the United States, the first‑generation composition patent is set to expire in 2032. In the EU it expires in 2030. Once those expire, generic manufacturers will be able to file for approval for a generic vonoprazan, subject to any remaining secondary patents or regulatory hurdles.
4. Country‑specific variations – Patent law varies by country. In some markets, Otsuka’s patents have already lapsed (e.g., certain Asian territories) or have never been granted, so generics may already be available there.
5. Checking the exact status – If you need definitive, up‑to‑date information for a particular jurisdiction, you can query the relevant patent office database (USPTO, JPO, EPO, etc.) or use global search tools such as WIPO’s PATENTSCOPE. Look for the “claim” numbers related to the core structure of vonoprazan (e.g., 1,4‑diazabicyclo[3.3.1]nonane‑2‑yl 1,2‑dichloromethanesulfonate).
---
Bottom line
- Vonoprazan’s core patents are still alive (through 2030–2032, depending on the region).
- Secondary patents further extend exclusivity for certain formulations and combinations.
- Generic entry is still several years away in most major markets.
If you’re looking at potential generics, licensing, or just want to know when you might see a cheaper alternative, keep an eye on those expiry dates and any new secondary patents that might be filed in the next few years.